Immunic’s (IMUX) “Outperform” Rating Reaffirmed at Leerink Partners

Immunic (NASDAQ:IMUX)‘s stock had its “outperform” rating reiterated by equities researchers at Leerink Partners in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $5.00 target price on the stock. Leerink Partners’ price target suggests a potential upside of 273.13% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. Piper Sandler reaffirmed an “overweight” rating and set a $28.00 price target on shares of Immunic in a report on Tuesday, July 16th. StockNews.com upgraded Immunic from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th. Finally, B. Riley started coverage on shares of Immunic in a research report on Tuesday, August 27th. They set a “buy” rating and a $6.00 price target on the stock. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $11.20.

Immunic Price Performance

Immunic stock opened at $1.34 on Monday. Immunic has a 52-week low of $0.95 and a 52-week high of $1.92. The stock has a fifty day moving average price of $1.36 and a two-hundred day moving average price of $1.31. The firm has a market capitalization of $120.71 million, a P/E ratio of -0.73 and a beta of 1.82.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.02. During the same quarter in the prior year, the company earned ($0.54) EPS. On average, equities research analysts predict that Immunic will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Immunic

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Sierra Summit Advisors LLC bought a new position in Immunic in the fourth quarter valued at about $487,000. Vanguard Group Inc. boosted its stake in shares of Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after purchasing an additional 1,703,047 shares during the last quarter. BVF Inc. IL acquired a new stake in shares of Immunic during the 1st quarter worth approximately $11,752,000. Janus Henderson Group PLC bought a new stake in shares of Immunic during the first quarter worth approximately $9,266,000. Finally, Ikarian Capital LLC lifted its holdings in Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after buying an additional 1,162,378 shares during the period. 51.82% of the stock is owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.